Subject(s)
Biological Factors/therapeutic use , Coronavirus Infections/epidemiology , Medication Adherence/statistics & numerical data , Pandemics/statistics & numerical data , Pneumonia, Viral/epidemiology , Veterans/statistics & numerical data , Adrenal Cortex Hormones/therapeutic use , Aged , Betacoronavirus , Biological Factors/administration & dosage , COVID-19 , Female , Humans , Inflammatory Bowel Diseases/drug therapy , Infusions, Intravenous/statistics & numerical data , Male , Middle Aged , Retrospective Studies , SARS-CoV-2 , United States/epidemiologySubject(s)
Coronavirus Infections/epidemiology , Gastrointestinal Agents/therapeutic use , Immunosuppressive Agents/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Pneumonia, Viral/epidemiology , Adult , Aged , Azathioprine/therapeutic use , Betacoronavirus , COVID-19 , Humans , Incidence , Infliximab/therapeutic use , Mercaptopurine/therapeutic use , Middle Aged , Pandemics , Retrospective Studies , SARS-CoV-2 , Tumor Necrosis Factor-alpha/antagonists & inhibitors , United States/epidemiology , United States Department of Veterans AffairsABSTRACT
INTRODUCTION: The clinic course of SARS-CoV-2 among patients with inflammatory bowel disease (IBD) has been extensively studied. However, there is a paucity of data on whether patients with IBD have an increased risk of developing SARS-CoV-2 with compared with patients without IBD. METHODS: We conducted a nationwide retrospective cohort study in the US Veterans' Affairs healthcare system from January 1, 2020, to June 30, 2020. We matched each patient with IBD with 2 patients without IBD on age, sex, race, location, and comorbidities. The outcome of interest was development of SARS-CoV-2. RESULTS: Among 38,378 patients with IBD and 67,433 patients without IBD, 87 (0.23%) and 132 (0.20%) patients developed incident SARS-CoV-2 infection, respectively (P = 0.29). DISCUSSION: Patients with IBD are not at a significantly increased risk of developing SARS-CoV-2 infection when compared with patients without IBD.